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INITIAL CONSIDERATIONS
Despite its high prevalence in individuals
with diabetes mellitus (DM) neuropathies
are the most underdiagnosed and under-
treated diabetic chronic complication (1).
The involvements of somatic and auto-
nomic nerve fibers in DM present complex
pathophysiologies (1–4). The impairment
of sympathetic and parasympathetic divi-
sions of the autonomic nervous system
(ANS) leads to diabetic autonomic neu-
ropathy (DAN), a condition that may affect
different organ systems such as cardiovas-
cular, gastrointestinal, genitourinary, sudo-
motor, and visual (4). Cardiovascular auto-
nomic neuropathy (CAN), within the con-
text of DAN, occurs when there is an
impairment of autonomic control of the
cardiovascular system after ruling out other
causes of dysautonomia (1).
It is known that CAN is an early and fre-
quent complication of DM, affecting from
7 to 15% of newly diagnosed patients to
90% of those in line for a double trans-
plant. In addition, CAN is among one of
the most disabling complications of DM in
terms of life expectancy and quality.
Clinical manifestations of CAN are
pleomorphic and appear in late stages,
and in isolation do not present enough
sensitivity and specificity for diagnosis
requiring the use of objective autonomic
tests (3, 4). Thus, detection of CAN in
a diabetic patient requires sensitive and
specific tests in order to establish differ-
ential diagnosis and quantify the sever-
ity of dysautonomia (3). Specifically, the
presence of symptoms or signs suggestive
of autonomic changes – such as erectile
dysfunction, dizziness, intermittent visual
impairment, postprandial hypotension,
resting tachycardia, or exercise intolerance
(dyspnea) in persons with DM – should be
investigated and confirmed by performing
objective diagnostic tests for CAN (3, 4).
DIAGNOSIS OF CARDIOVASCULAR
AUTONOMIC NEUROPATHY
The recent Toronto Consensus concluded
that currently the five most sensitive and
specific methods to assess the presence of
CAN are (4): (A) Study of heart rate vari-
ability (HRV) using the ratio of the RR
intervals of the electrocardiogram (ECG);
(B) Baroreflex sensitivity (BRS); (C) Mus-
cle sympathetic nerve activity (MSNA);
(D) Measurement of plasma levels of cat-
echolamines (PLC); (E) Cardiac sympa-
thetic mapping (CSM).
Heart rate (HR) variability is recog-
nized as a chaotic signal with hidden con-
stituents. HRV can be defined as an oscil-
lation of RR intervals between each heart
beat that occurs as a result of ANS sym-
pathetic and parasympathetic activities on
the sinus node (6, 7). The hypothesis that
reduction of HRV reflects the suppression
of vagal modulation and sympathetic dom-
inance, resulting in higher mortality and
arrhythmia, has been used as the basis for
numerous studies, which have consistently
confirmed this relationship (2, 4, 5, 7).
Heart rate variability measurements
are obtained with an analysis of sponta-
neous or experimentally induced fluctu-
ations of RR intervals in the ECG. The
methods currently accepted include car-
diovascular autonomic reflex tests (CARTs)
(experimentally induced variations of RR)
and time and frequency-domain methods
(spontaneous variations of RR). Time and
frequency-domain tests measure, respec-
tively, the overall magnitude of the fluctua-
tions of RR intervals between each heart
beat around the average value and the
magnitude of fluctuations in a predeter-
mined range of frequency. Time-domain
measurements can be assessed by statistical
analysis of RR intervals while frequency-
domain measurements by spectral analysis
of an array (1–4, 6–8).
Spectral analysis uses a mathematical
algorithm (autoregression analysis or fast
Fourier transform) to turn HRV – a com-
plex biological signal – into its causal com-
ponents, presenting them according to the
frequency in which they alter the RR (1,
2, 6, 7). The result (spectral amplitude) is
presented in a graph consisting of Ampli-
tude (Y axis) vs. Frequency (X axis). The
spectral amplitude does not only reflect
the magnitude of HRV (Y axis), but also
the oscillations in different frequencies, i.e.,
the number of HR fluctuations per sec-
ond (X axis). It has been demonstrated that
the total spectral amplitude (total power or
TP) of HRV consists of three key frequency
bands:
(1) Very low-frequency component or
VLF (from 0.01 to 0.04 Hz): this com-
ponent is related to the fluctuations
in vasomotor tonus associated with
thermoregulation and sweating (sym-
pathetic control);
(2) Low-frequency component or LF
(from 0.04 to 0.15 Hz): this compo-
nent is related to the baroreflex (sym-
pathetic control with vagal modula-
tion);
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(3) High-frequency component or HF
(from 0.15 to 0.5 Hz): this compo-
nent is related to changes in RR
according to the phases of breath-
ing (inhale/exhale), which are under
parasympathetic control.
In spite of ambulatory blood pressure
monitoring (ABPM) being a reliable tool
to assess BP patterns within 24 h, ABPM as
well as the QT interval (QTi) are tests that
are not sensitive enough for the diagnosis
of CAN (3, 4), however, when such tests are
altered CARTs should be performed (level
B recommendation).
Baroreflex sensitivity is a technique
used to assess cardiac baroreflex func-
tion by combining information from HR
and blood pressure (BP). Theoretically,
this technique evaluates the two afferent
sections of the cardiovascular ANS: sympa-
thetic (arterial vasoconstriction) and vagal
(bradycardia or tachycardia) in response to
changes induced in BP. In practice, how-
ever, only the cardio-vagal section ends up
being analyzed due to technical difficulties
in assessing arteriolar sympathetic tone. To
date, there is no data on the sensitivity and
specificity of this method for diagnosing
CAN, and the technique requires continu-
ous monitoring of BP through finapress.
Muscle sympathetic nerve activity is
an invasive method (and not feasible in
routine clinical practice) to directly assess
conduction of the peripheral sympathetic
nervous system through microneurogra-
phy. Routinely, it is not recommended for
the diagnosis of CAN.
Evaluating the PLC (adrenaline, nora-
drenaline, and its metabolites) has not
been proven to be useful for the stag-
ing or diagnosis of CAN, although PLC
has a remarkable role in the differential
diagnosis of other endocrine pathologies
such as pheochromocytoma and medullary
adrenal insufficiency.
Cardiac sympathetic imaging tech-
niques (PET and SPECT) directly assess
sympathetic innervation through scintig-
raphy or CSM using radiolabeled cate-
cholamines actively captured by sympa-
thetic nerve terminals. Due to its high
cost, lacks of reference values and of stan-
dardized methodology, and also its suscep-
tibility to ischemia interference (because
the result depends directly on myocar-
dial perfusion), these techniques are not
recommended for routine diagnosis of
CAN and currently remain restricted to the
research field.
In summary, early diagnosis of CAN
is imperative in patients with DM, both
type 2 (from diagnosis) and type 1 (5 years
after diagnosis). Currently, CARTs are the
gold standard for diagnosing CAN in per-
sons with DM (6, 8) and include four
tests: (i) deep breathing (E:I), (ii) Valsalva,
(iii) orthostatic (30:15), and (iv) orthosta-
tic hypotension (OH). Maneuvers used in
the first three tests induce changes in HRV
that primarily assess the parasympathetic
ANS [level B recommendation by the Ital-
ian (3) and Toronto (4) Consensuses]. In
contrast, OH or the variation in systolic BP
in supine and standing positions evaluates
the function of the sympathetic ANS (level
B recommendation) (3, 4). A review of the
technical aspects of the methodology used
by Diabetic Neuropathy Study Group of the
Italian Society of Diabetology can be found
in reference (3) while the protocol used by
the authors at the Federal University of São
Paulo (Diabetes Center) can be found in
reference (2).
CRITICAL ANALYSIS OF HRV
In 1996, a task force directed by the Euro-
pean Society of Cardiology and the Ameri-
can Society of Electrophysiology proposed
the standardization of parameters and the
clinical use of autonomic tests for the diag-
nosis of CAN, specifically in DM (6). The
proposed guidelines met the objectives,
however, they emphasized computational
measurement and techniques to the detri-
ment of the physiological interpretations
of HRV. Furthermore, consistent values for
normal measurements of HRV in different
populations and by age bracket and gender
were not defined (6, 10).
Technological progress, through high
level computerization, has allowed a broad
application of methods to study the ANS
through HRV analysis. In these methods,
the biological signs of the ANS are obtained
indirectly and may be affected by factors
unrelated to the activity of the ANS, thereby
leading to potentially inadequate or con-
fusing results. We emphasize the need for
knowledge of physiology and pathophys-
iology in order to correctly understand,
apply, and interpret autonomic tests, as
well as the various factors that can alter
their results, such as age, gender, body
position, time of day, prior physical activity,
nutrition, BP, HR, respiratory rate baseline,
coffee ingestion, use of cigarettes, mental
stress, hyperglycemia and hypoglycemia,
and insulinemia. Hyperinsulinemia seems
to be related to an increase in plasma nor-
epinephrine and a decrease in parasympa-
thetic control of HR caused by insulin itself
(11). Furthermore, insulin affects blood
vessel tone and can induce vasodilation and
hypotension. Besides the above named fac-
tors that may influence the outcome of
autonomic tests, it is crucial to reinforce
that the biological signal (HRV) has to
be obtained through the ECG (RR inter-
vals), and that a capable professional must
dominate its interpretation because a sin-
gle unrecognized extrasystole could distort
all test results (6, 10).
Recent efforts, through consensus of
authorities, recommend the adoption of
standardized techniques in the applica-
tion and interpretation of autonomic tests
according to the pathophysiology and con-
founding factors present in cardiovascular
examinations. The Toronto (4) and Italian
(3) Consensuses treated CARTs as the gold
standard for the diagnosis of CAN in DM.
The Italian Consensus (3) established
the lack of an individual and effective test
for the diagnosis of CAN. In contrast, the
application of various tests (which assess
both divisions of the ANS, parasympa-
thetic, and sympathetic) reduces the likeli-
hood of false positives (3, 4, 8). The Italian
Consensus (3) omitted the other ways of
measuring HRV, however, the international
Toronto Consensus (4, 8) advocates the
use of a set of HRV measurements beyond
the four reflex tests currently considered
the gold standard. For example, adding
three tests of analysis in the frequency-
domain (spectral analysis) to the CARTs
(four tests), totaling seven tests (1, 2, 4, 8).
CLINICAL RELEVANCE
Cardiovascular autonomic neuropathy has
been recognized as a significant cause
of morbidity and mortality in diabetic
patients since the 1970s. But only in recent
years CAN was proven to have a predictive
power for primary cardiovascular events
(non-fatal myocardial infarction, stroke,
and sudden cardiac death) greater than the
classical risk factors such as smoking, LDL
levels, and family history of coronary artery
disease. DIAD-1 (12) and DIAD-3 (13)
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Table 1 | Indications for the cardiovascular autonomic reflex tests (CARTs)*.
1. Diagnosis and Staging of CAN in Type 2 DM patients (at diagnosis and annually thereafter)
2. Diagnosis and Staging of CAN inType 1 DM patients (5 years after diagnosis and annually thereafter)
3. Stratification of Cardiovascular risk: in pre-operatory testing, pre-physical activity, indication of
selective beta-blocker, and suspected silent ischemia
4. Differential Diagnosis of other manifestations of DAN (regardless of DM duration): assess whether
gastroparesis, erectile dysfunction, orthostatic hypotension, dizziness, syncope, or tachycardia in
diabetic persons are due to dysautonomia
5. Evaluate the progression of autonomic failure and monitor response to therapy (e.g., continuous
infusion of insulin, post-transplants, and use of antioxidants)
6. Differential diagnosis of other causes of neuropathy such as autoimmune autonomic neuropathy
(CIDP, Celiac Disease, Amyotrophy) or toxic-infectious neuropathy (alcohol, Hansen, HIV) as well as
in cases where the presence of autonomic neuropathy is disproportionate to the sensory-motor
neuropathy
*Modified from Ref. (3) and (4).
DM-2, Type 2 diabetes mellitus; DM-1, Type 1 diabetes mellitus; DAN, diabetic autonomic neuropathy; CIDP,
chronic inflammatory demyelinating polyneuropathy; HIV, human immunodeficiency virus.
prospective studies showed unequivocally
that the abnormal Valsalva test resulted
in a relative risk 3.0 and 4.5 times
higher for primary cardiovascular event
and silent myocardial ischemia, respec-
tively (5, 12, 13). Further reinforcing
such concepts, one of the greatest lega-
cies of the well-known ACCORD study
was precisely the role of cardiovascular
dysautonomia, which doubled the risk
of death in diabetics with CAN and
concomitant sensory-motor polyneuropa-
thy (14).
Recently, the Toronto Consensus estab-
lished four reasons why the diagnosis of
CAN is relevant to clinical practice:
(1) For diagnosing and staging the dif-
ferent clinical forms of CAN: initial,
definite, and advanced or severe;
(2) For the differential diagnosis of clinical
manifestations (e.g., resting tachycar-
dia, OH, and dyspnea upon exercise)
and their respective treatment;
(3) For stratifying the degree of cardio-
vascular risk and the risk of other
diabetic complications (nephropathy,
retinopathy, and silent myocardial
ischemia);
(4) To adapt the goal of glycated hemoglo-
bin (HbA1c) in each patient: for exam-
ple, those with severe CAN should
have a less aggressive glycemic con-
trol due to the risk of asymptomatic
hypoglycemia in these patients while
patients with initial stages of CAN
should have a more intensive glycemic
control.
The main clinical indications of the
autonomic reflex tests are summarized in
Table 1.
Although it goes beyond the scope of
this analysis, it is worth remembering that
two lines of research have shown promising
results in the treatment of diabetic CAN:
(1) A still-experimental line in rats using
“chaperones” (heat shock proteins) (15),
and (2) A phase three of human therapeutic
clinical trial utilizing weekly subcutaneous
C-peptide in patients with type 1 DM and
polyneuropathy with dysautonomia (16).
FINAL CONSIDERATIONS
There is an apparent neglect in the diag-
nosis of CAN in diabetic persons as result
of: low interest in an unfamiliar compli-
cation, skepticism concerning therapeutic
options, lack of understanding diagnostic
utility, and the necessity of education and
training related to cardiovascular tests, as
pointed out by the Italian Consensus (3),
in spite of increasingly consistent evidence
of its predictive value for cardiovascular
morbidity and mortality (14).
Despite the Toronto Consensus (4) hav-
ing determined HRV analysis to be the
most sensitive and specific method, there
is no unanimous criteria for the diagnosis
of CAN (4, 8). Furthermore, there is con-
troversy regarding the best way to include
measurements of the ANS in the daily clini-
cal routine (9). In a recent review, Vinik (7)
affirms emphatically the need to promote
more aggressive strategies and therapeutic
approaches in favor of patients with CAN.
A proactive position toward diabetics with
burning feet or any suspected dysautono-
mia requires an objective, safe and accurate
investigation of CAN through the use of
CARTs.
In conclusion, CARTs as well as time
and frequency-domain HRV analysis pro-
vide key information regarding the sym-
pathetic and parasympathetic modulation
of the cardiovascular system; all of which
represent a clinically relevant method for
the diagnosis of CAN. However, the correct
application of the technique (RR intervals
of the ECG) is critical, and the method-
ology depends, also critically, on the cor-
rect understanding of the underlying phys-
iological and pathophysiological mecha-
nisms, the mathematical model used, the
bias factors, and possible technical artifacts.
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